Matches in SemOpenAlex for { <https://semopenalex.org/work/W2971317504> ?p ?o ?g. }
Showing items 1 to 93 of
93
with 100 items per page.
- W2971317504 endingPage "TPS4138" @default.
- W2971317504 startingPage "TPS4138" @default.
- W2971317504 abstract "TPS4138 Background: VEGF inhibition in gastric cancer shows promising improvement of remission rate and progression-free survival (Ohtsu et al., JCO 2011). Pazopanib is an orally available tyrosine kinase inhibitor (TKI) selectively inhibiting VEGFR-1, -2, -3, c-kit and PDGFR. It is approved for treating renal cell cancer. A phase-I trial showed good tolerability of pazopanib with full-dose FOLFOX in solid tumors (Brady et al., ASCO, 2009). FLO is a widely used combination for advanced gastric cancer recommended in national guidelines. Methods: 75 Patients with HER-2-negative locally advanced or metastatic adenocarcinoma of the stomach or the gastro-esophageal junction will be randomized in a 2:1 ratio to A: FLO (F 2600mg/m2 as 24h infusion, L 200mg/m2, O 85 mg/m2) d1 + pazopanib (800mg) d1-14 and B: FLO; repeated for 12 2-week cycles, followed by a maintenance therapy with pazopanib alone in A and an observation period in B until disease progression. Primary endpoint is progression-free survival rate (PFSR) at 6 months, secondary endpoints are PFSR at 9 and 12 months, median PFS, response rate, duration of response, toxicity, tolerability and overall survival. Additionally, we evaluate the predictive and prognostic relevance of PIGF, VEGF, and the respective soluble receptors sVEGFR1 and sVEGFR2 as biomarkers for clinicopathological parameters, clinical response to treatment and tumor volume change. Based on a phase-III trial demonstrating a 6-month PFSR of 44% with FLO (Al-Batran et al., 2008), we estimate a 6-month PFSR of 55% in the experimental group. Given an alpha error of 0.1 and a beta error of 0.2 in a Simon 2-stage minimax design, in the first stage ≥12 of 30 patients need to be progression free at 6 months to continue and after the second stage ≥25 of 50 patients should be progression free at 6 months to justify further evaluation. Randomization is performed to estimate selection bias according to pazopanib-specific exclusion criteria for comparison with historical data. Study protocol received ethics committee approval in November 2011 and is currently recruiting patients in 15 AIO centers." @default.
- W2971317504 created "2019-09-05" @default.
- W2971317504 creator A5007216221 @default.
- W2971317504 creator A5013695170 @default.
- W2971317504 creator A5023783108 @default.
- W2971317504 creator A5038131926 @default.
- W2971317504 creator A5059926741 @default.
- W2971317504 creator A5064643995 @default.
- W2971317504 creator A5072163653 @default.
- W2971317504 creator A5078248078 @default.
- W2971317504 creator A5085406499 @default.
- W2971317504 date "2012-05-20" @default.
- W2971317504 modified "2023-10-17" @default.
- W2971317504 title "PaFLO: Pazopanib with 5-fluorouracil, leucovorin, and oxaliplatin (FLO) as first-line treatment in advanced gastric cancer: A randomized phase II study of the Arbeitsgemeinschaft internistische Onkologie (AIO)." @default.
- W2971317504 doi "https://doi.org/10.1200/jco.2012.30.15_suppl.tps4138" @default.
- W2971317504 hasPublicationYear "2012" @default.
- W2971317504 type Work @default.
- W2971317504 sameAs 2971317504 @default.
- W2971317504 citedByCount "1" @default.
- W2971317504 countsByYear W29713175042021 @default.
- W2971317504 crossrefType "journal-article" @default.
- W2971317504 hasAuthorship W2971317504A5007216221 @default.
- W2971317504 hasAuthorship W2971317504A5013695170 @default.
- W2971317504 hasAuthorship W2971317504A5023783108 @default.
- W2971317504 hasAuthorship W2971317504A5038131926 @default.
- W2971317504 hasAuthorship W2971317504A5059926741 @default.
- W2971317504 hasAuthorship W2971317504A5064643995 @default.
- W2971317504 hasAuthorship W2971317504A5072163653 @default.
- W2971317504 hasAuthorship W2971317504A5078248078 @default.
- W2971317504 hasAuthorship W2971317504A5085406499 @default.
- W2971317504 hasConcept C121608353 @default.
- W2971317504 hasConcept C126322002 @default.
- W2971317504 hasConcept C141071460 @default.
- W2971317504 hasConcept C143998085 @default.
- W2971317504 hasConcept C168563851 @default.
- W2971317504 hasConcept C197934379 @default.
- W2971317504 hasConcept C203092338 @default.
- W2971317504 hasConcept C2776694085 @default.
- W2971317504 hasConcept C2778260052 @default.
- W2971317504 hasConcept C2778375690 @default.
- W2971317504 hasConcept C2778439243 @default.
- W2971317504 hasConcept C2779490328 @default.
- W2971317504 hasConcept C2780739268 @default.
- W2971317504 hasConcept C2780962732 @default.
- W2971317504 hasConcept C2908647359 @default.
- W2971317504 hasConcept C31760486 @default.
- W2971317504 hasConcept C526805850 @default.
- W2971317504 hasConcept C535046627 @default.
- W2971317504 hasConcept C71924100 @default.
- W2971317504 hasConcept C90924648 @default.
- W2971317504 hasConcept C99454951 @default.
- W2971317504 hasConceptScore W2971317504C121608353 @default.
- W2971317504 hasConceptScore W2971317504C126322002 @default.
- W2971317504 hasConceptScore W2971317504C141071460 @default.
- W2971317504 hasConceptScore W2971317504C143998085 @default.
- W2971317504 hasConceptScore W2971317504C168563851 @default.
- W2971317504 hasConceptScore W2971317504C197934379 @default.
- W2971317504 hasConceptScore W2971317504C203092338 @default.
- W2971317504 hasConceptScore W2971317504C2776694085 @default.
- W2971317504 hasConceptScore W2971317504C2778260052 @default.
- W2971317504 hasConceptScore W2971317504C2778375690 @default.
- W2971317504 hasConceptScore W2971317504C2778439243 @default.
- W2971317504 hasConceptScore W2971317504C2779490328 @default.
- W2971317504 hasConceptScore W2971317504C2780739268 @default.
- W2971317504 hasConceptScore W2971317504C2780962732 @default.
- W2971317504 hasConceptScore W2971317504C2908647359 @default.
- W2971317504 hasConceptScore W2971317504C31760486 @default.
- W2971317504 hasConceptScore W2971317504C526805850 @default.
- W2971317504 hasConceptScore W2971317504C535046627 @default.
- W2971317504 hasConceptScore W2971317504C71924100 @default.
- W2971317504 hasConceptScore W2971317504C90924648 @default.
- W2971317504 hasConceptScore W2971317504C99454951 @default.
- W2971317504 hasIssue "15_suppl" @default.
- W2971317504 hasLocation W29713175041 @default.
- W2971317504 hasOpenAccess W2971317504 @default.
- W2971317504 hasPrimaryLocation W29713175041 @default.
- W2971317504 hasRelatedWork W2286288743 @default.
- W2971317504 hasRelatedWork W2518765238 @default.
- W2971317504 hasRelatedWork W2584220919 @default.
- W2971317504 hasRelatedWork W2589351745 @default.
- W2971317504 hasRelatedWork W2620160838 @default.
- W2971317504 hasRelatedWork W3004551912 @default.
- W2971317504 hasRelatedWork W3088473445 @default.
- W2971317504 hasRelatedWork W3167650053 @default.
- W2971317504 hasRelatedWork W4205087106 @default.
- W2971317504 hasRelatedWork W4382806805 @default.
- W2971317504 hasVolume "30" @default.
- W2971317504 isParatext "false" @default.
- W2971317504 isRetracted "false" @default.
- W2971317504 magId "2971317504" @default.
- W2971317504 workType "article" @default.